lovotibeglogene autotemcel Lyfgenia
Selected indexed studies
- Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) for individuals 12 years and older with sickle cell disease (SCD) and recurrent vaso-occlusive crises (VOC): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG). (Genet Med Open, 2024) [PMID:39822266]
- Hematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review. (Cell Transplant, 2024) [PMID:38680015]
- Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia. (Med Sci Monit, 2024) [PMID:38425279]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia. (2024) pubmed
- Hematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review. (2024) pubmed
- Newer Modalities and Updates in the Management of Sickle Cell Disease: A Systematic Review. (2024) pubmed
- Advances in Gene Therapy for Sickle Cell Disease: From Preclinical Innovations to Clinical Implementation and Access Challenges. (2025) pubmed
- Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) for individuals 12 years and older with sickle cell disease (SCD) and recurrent vaso-occlusive crises (VOC): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG). (2024) pubmed
- Gene Therapies for Hemoglobinopathies: Efficacy, Cell Collection & Transfusion Support. (2025) pubmed
- Advances in Sickle Cell Disease Treatment: A Comparative Review of Hematopoietic Stem Cell Transplantation and Gene Therapy (Casgevy and Lyfgenia). (2025) pubmed
- FDA approval of Casgevy and Lyfgenia: a dual breakthrough in gene therapies for sickle cell disease. (2024) pubmed
- Updated Review of Current Therapeutic Approaches for the Management of Sickle Cell Disease. (2025) pubmed
- CRISPR-Cas editing technologies for viral-mediated gene therapies of human diseases: Mechanisms, progress, and challenges. (2026) pubmed